Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Vivos is a medical technology company pivoting from a legacy model of training dentists (VIPs) to a new model involving the acquisition and operation of sleep centers. The primary driver of recent activity is the June 10, 2025, acquisition of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada, to directly diagnose and treat obstructive sleep apnea (OSA) patients.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $6,783 | $3,860 | $13,619 | $11,333 |
| Gross Profit | $3,937 | $2,334 | $7,554 | $6,922 |
| Gross Margin | 58% | 60% | 55% | 61% |
| Operating Loss | $(4,734) | $(2,645) | $(13,512) | $(8,365) |
| Net Loss | $(5,400) | $(2,616) | $(14,276) | $(8,309) |
| Cash and Equivalents (End of Period) | $3,087 | $6,311 | $3,087 | $6,311 |
| Total Debt (Current + Long-term) | $8,718 | $0 | $8,718 | $0 |
| Accumulated Deficit | $(118,464) | $(101,360) | $(118,464) | $(101,360) |
Note: Debt figures include the $8.3M principal note issued for the SCN acquisition, net of issuance costs and discounts.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 76% year-over-year in Q3 2025 ($6.8M vs. $3.9M). This was driven by the inclusion of SCN operations, which contributed $2.2M in sleep testing services and $1.3M in treatment center revenue.
- Expense Surge: Operating expenses increased significantly, with General and Administrative (G&A) expenses rising 76% to $7.9M in Q3 2025. This increase is attributed to integration costs, professional fees, and personnel costs associated with the SCN acquisition.
- Debt Incurrence: The company incurred $8.3M in senior secured debt in June 2025 to fund the SCN acquisition. This represents a material change from the prior period where the company had no debt.
- Legacy Model Decline: Revenue from the legacy VIP enrollment model decreased substantially as the company ceased recruitment of new VIP dentists. VIP revenue is expected to cease entirely by the end of 2026.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Business Pivot: Management is fully engaged in the "Sleep Optimization" (SO) team model at SCN. Currently, 1.5 SO teams are deployed, with plans to add two more by year-end 2025 and a fourth in Q1 2026.
- Capacity Constraints: Patient demand currently exceeds capacity. The company is processing less than 40% of patients seeking appointments due to physical space limitations and staffing constraints.
- Financial Sustainability: Management states that current cash levels ($3.1M) are insufficient to fund operations for the next 12 months. Additional financing is required to continue as a going concern.
- Future Strategy: The company plans to replicate the SCN acquisition model or utilize a revised management services entity model (jointly owned with providers) to expand into new markets, such as the upcoming facility in Auburn Hills, Michigan.
Risks and Contingencies
- Going Concern: The filing explicitly states that without additional financing, there is substantial doubt regarding the company's ability to continue as a going concern.
- Debt Servicing: The $8.3M note carries a 9% interest rate and includes a monitoring fee. Failure to service this debt could lead to default and asset liquidation.
- Integration Risks: The new business model is unproven at scale. Challenges include recruiting qualified clinical staff, credentialing, and navigating "Corporate Practice of Medicine" laws.
- Regulatory and Legal: Ongoing litigation with Ortho-Tain, Inc. is in mediation. Additionally, the company faces risks related to insurance reimbursement rates and potential audits of billing practices.
Investor Verification Checklist
- Cash Runway: Verify the timeline and terms of any new equity or debt financing required to bridge the liquidity gap identified in the "Going Concern" warning.
- SCN Integration Progress: Monitor the deployment of additional Sleep Optimization (SO) teams and the resulting impact on revenue per team versus the projected $500k/month contribution margin.
- Debt Covenants: Review the specific covenants and redemption rights of the $8.3M Streeterville Capital note, particularly the monthly redemption option available to the lender starting six months post-issuance.
- Legacy Revenue Wind-down: Track the decline in VIP enrollment revenue to ensure it aligns with the projected cessation by end of 2026.
- Legal Settlement: Confirm the status of the Ortho-Tain litigation settlement negotiations and any potential financial impact.